Get started
Author

Vinod Vijay Subhash

Observed names: Subhash, Vinod V, V. Subhash, Vinod Subhash, Vinod V. Subash, Vinod V. Subhash, Vinod Vijayasubhash
Observed institutions: University of Leeds, National University of Singapore, University of Cambridge, UNSW Sydney, MRC Cancer Unit, Hutchison/MRC Research Centre, National University Hospital, National University Health System, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Science Institute of Singapore
ORCID: 0000-0001-6050-9915
Observed ORCID: 0000-0001-6050-9915
OpenAlex ID: A5012541057
Characterization of the Sporulation Initiation Pathway of Clostridium difficile and Its Role in Toxin Production
2009 · Sarah Underwood, Shuang Guan, et al. · Journal of Bacteriology · 185
Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data
2020 · SriGanesh Jammula, Annalise C. Katz-Summercorn, et al. · Gastroenterology · 112
PDF
Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
2018 · Vinod Vijay Subhash, Mei Shi Yeo, et al. · Scientific Reports · 103
PDF
Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling
2018 · Lingzhi Wang, Nicholas Li-Xun Syn, et al. · Cancer Letters · 82
GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells
2015 · Vinod Vijay Subhash, Shi Hui Tan, et al. · BMC Cancer · 59
PDF
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
2025 · Edmond M. Kwan, Sarah W. S. Ng, et al. · Nature Medicine · 51
Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer
2016 · Chen Xie, Vinod Vijay Subhash, et al. · Cellular Oncology · 38
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
2015 · Vinod Vijay Subhash, Mei Shi Yeo, et al. · Journal of Immunology Research · 36
PDF
ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis
2016 · Vinod Vijay Subhash, Shi Hui Tan, et al. · Molecular Cancer Therapeutics · 33
Inflammation and proliferation – a causal event of host response to Helicobacter pylori infection
2015 · Vinod Vijay Subhash, Bow Ho · Microbiology · 29
Extracellular galectin-3 counteracts adhesion and exhibits chemoattraction in Helicobacter pylori-infected gastric cancer cells
2016 · Vinod Vijay Subhash, Samantha Shi Min Ling, et al. · Microbiology · 26
FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway
2019 · Mei Shi Yeo, Vinod Vijay Subhash, et al. · Cancers · 20
PDF
Galectin 3 acts as an enhancer of survival responses in H. pylori-infected gastric cancer cells
2016 · Vinod Vijay Subhash, Bow Ho · Cell Biology and Toxicology · 19
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma
2021 · Vinod Vijay Subhash, Libby Huang, et al. · British Journal of Cancer · 17
PDF
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
2024 · Nima Sharifi, Robert Diaz, et al. · Journal of Clinical Investigation · 9
PDF
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).
2024 · Edmond Michael Kwan, Michael S Hofman, et al. · Journal of Clinical Oncology · 7
PDF
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
2025 · Soumyajit Roy, Yilun Sun, et al. · Nature Communications · 6
PDF
Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials
2026 · Christopher J. Sweeney, Vrishab Krishna, et al. · JCO Precision Oncology · 5
PDF
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
2025 · H.-M. Lin, T. Scheinberg, et al. · Annals of Oncology · 5
The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus
2020 · Wladyslaw Januszewicz, Vinod V. Subhash, et al. · EBioMedicine · 4
PDF
Analytical Quality Controls for ddPCR Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia
2021 · Dan Chen, Rosemary Sutton, et al. · Clinical Chemistry · 3
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026 · Sebastian Medina, Naoto Tokuyama, et al. · Clinical Cancer Research · 2
Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.
2026 · Christopher Sweeney, James A. Proudfoot, et al. · Journal of Clinical Oncology · 1
An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
2026 · Sebastian R. Medina, Naoto Tokuyama, et al. · Journal of Clinical Oncology · 1
Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).
2025 · Lisa Horvath, Hui-Ming Lin, et al. · Journal of Clinical Oncology · 1
PDF
Works count: 59
Citation count: 854
H-index: 14
I10-index: 14
Year
Topic
Type